CLINICAL SCIENCE Mode of presentation and time to treatment of uveal melanoma in Finland
نویسندگان
چکیده
Aims: To investigate the current referral pattern and delays in treatment of patients with primary uveal melanoma. Methods: 184 consecutive Finnish patients with uveal melanoma diagnosed between July 1994 and June 1999 were eligible, and 159 were enrolled (inclusion rate, 86%). Their mean age was 60 years (range 14–87). The dates of visits to dispensing optician, physician, ophthalmologist and ocular oncologist, the presence of symptoms, and reason for consultation were determined by structured telephone interview. Time intervals to treatment planning and treatment were calculated. Results: 139 patients (87%) had symptoms at presentation and 44 patients (28%) had been seen by an ophthalmologist less than 2 years previously. The median height of the tumour was 6 mm (range, 1.0–17.0) and its largest basal diameter 11 mm (range 2.5–22.0) at diagnosis. Melanoma developed from a previously detected presumed naevus in 13 patients (8%). When the first contact was a dispensing optician (15%) the median time to treatment planning was 22 days (range 1–1156). When a physician other than an ophthalmologist (19%) was contacted the delay was 68 days (range 0–1283) and when an ophthalmologist (65%) was seen it was 34 days (range 1–1426). These differences were not significant (p=0.32). The chance of being referred at first visit was 89%. Median time to treatment was not associated with symptoms (p=0.16) and tumour volume (p=0.29), but it was significantly different between patients who were and were not referred at first visit (140 days v 34 days; p<0.001) and between those treated by ruthenium and iodine brachytherapy (59 days v 33 days; p=0.009). Conclusions: Analysis of delays in management indicates that earlier treatment could be achieved if dilated fundus examinations were performed without exceptions, all suspicious naevi were referred for a second opinion, and if the patients with melanoma were referred to the ocular oncology service concurrently with staging examinations done at the regional hospital.
منابع مشابه
Silastic Thickness Optimization in Uveal Melanoma Brachytherapy by Monte Carlo Method
Introduction In order to treat uveal Melanoma , first, radioactive seeds are laid on a silicone- made substance which is called Silastic after that they are inserted in the plaque, and finally, this plaque containing silicone-made substance is stitched to the sclera surface. The dose gradient within the tumor and healthy tissues can be varied due to changing the Silastic thickness between scler...
متن کاملA new model for Spread Out Bragg Peak in proton therapy of uveal melanoma
In this research, in order to improve our calculations in treatment planning for proton radiotherapy of ocular melanoma, we improved our human eye phantom planning system in GEANT4 toolkit. Different analytical models have investigated the creating of Spread Out Bragg Peak (SOBP) in the tumor area. Bortfeld’s model is one of the most important analytical methods. Using convolution method, a new...
متن کاملMode of presentation and time to treatment of uveal melanoma in Finland.
AIMS To investigate the current referral pattern and delays in treatment of patients with primary uveal melanoma. METHODS 184 consecutive Finnish patients with uveal melanoma diagnosed between July 1994 and June 1999 were eligible, and 159 were enrolled (inclusion rate, 86%). Their mean age was 60 years (range 14-87). The dates of visits to dispensing optician, physician, ophthalmologist and ...
متن کاملMonte Carlo simulation of two 106Ru eye plaques in a new mathematical human eye model
BEBIG Ruthenium-106 ophthalmic plaques have been used for treatment of uveal melanoma, retinoblastoma, melanoma of the iris and other special applications for many years. The plaques consist of a thin film of 106Ru, a beta emitter, encapsulated in pure silver. The present work proposes a new mathematical eye model for ophthalmic brachytherapy dosimetry. This new mod...
متن کاملLong-Term Survivors with Metastatic Uveal Melanoma
BACKGROUND To report the tumor, patient, and treatment characteristics of long-term metastatic uveal melanoma survivors. METHODS A non-comparative, retrospective case series of patients from a single institution surviving >24 months with metastatic uveal melanoma (UM). RESULTS Nine patients met the study criteria and their charts were reviewed. The mean age at diagnosis of UM was 44.1 years...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2002